Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Primary Progressive Multiple Sclerosis (PPMS) Market Statistics, Facts & Figures, Growth Overview, Size & Share

(Albany,US) DelveInsight has launched a new report on Primary Progressive Multiple Sclerosis Market 

DelveInsight’s “Primary Progressive Multiple Sclerosis (PPMS) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS), historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Primary Progressive Multiple Sclerosis (PPMS) market report provides current treatment practices, emerging drugs, Primary Progressive Multiple Sclerosis (PPMS) market share of the individual therapies, current and forecasted Primary Progressive Multiple Sclerosis (PPMS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Progressive Multiple Sclerosis (PPMS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According to the National Multiple sclerosis Society, primary-progressive multiple sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain’s ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe. PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions. PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapse or new MRI activity) or without progression. The occurrence and severity of PPMS symptoms vary with each person. Symptoms include headaches, pain in the legs and feet, back pain, muscle spasms, trouble in walking, vision problems, etc. In addition, this condition affects men and women equally.

View Free Sample Page:- https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market

Primary Progressive Multiple Sclerosis Treatment

The DelveInsight Primary Progressive Multiple Sclerosis (PPMS) market report gives a thorough understanding of the Primary Progressive Multiple Sclerosis (PPMS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.  This segment of the report covers the detailed diagnostic methods or tests for Primary Progressive Multiple Sclerosis (PPMS).  It covers the details of conventional and current medical therapies available in the Primary Progressive Multiple Sclerosis (PPMS) market for the treatment of the condition. It also provides Primary Progressive Multiple Sclerosis (PPMS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Primary Progressive Multiple Sclerosis Pipeline

The dynamics of the primary-progressive multiple sclerosis (PPMS) market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rise in the awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period of 2020–2030. Some of the key players in the therapeutic market of PPMS at the global level are MedDay Pharma, MediciNova, Mapi Pharma, Brainstorm-Cell Therapeutics etc. While some of the companies have recently shifted their focus towards this indication, yet others are expected to create a significant influence on the market size during the forecast period.

Primary Progressive Multiple Sclerosis Report Scope

  • The report covers the descriptive overview of Primary Progressive Multiple Sclerosis (PPMS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Primary Progressive Multiple Sclerosis (PPMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Primary Progressive Multiple Sclerosis (PPMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Progressive Multiple Sclerosis (PPMS) market.

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market

Table of content

1. Key Insights

2. Executive Summary of Primary Progressive Multiple Sclerosis (PPMS)

3. Competitive Intelligence Analysis for Primary Progressive Multiple Sclerosis (PPMS)

4. Primary Progressive Multiple Sclerosis (PPMS): Market Overview at a Glance

5. Primary Progressive Multiple Sclerosis (PPMS): Disease Background and Overview

6. Patient Journey

7. Primary Progressive Multiple Sclerosis (PPMS) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Primary Progressive Multiple Sclerosis (PPMS) Treatment

11. Marketed Products

12. Emerging Therapies

13. Primary Progressive Multiple Sclerosis (PPMS): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Progressive Multiple Sclerosis (PPMS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Primary Progressive Multiple Sclerosis (PPMS) market
  • To understand the future market competition in the Primary Progressive Multiple Sclerosis (PPMS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Progressive Multiple Sclerosis (PPMS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Progressive Multiple Sclerosis (PPMS) market
  • To understand the future market competition in the Primary Progressive Multiple Sclerosis (PPMS) market

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Growth Hormone Deficiency (GHD) Market Statistics, Facts & Figures, Growth Overview, Size & Share

(Albany,US) DelveInsight has launched a new report on Growth Hormone Deficiency Market

DelveInsight’s “Growth Hormone Deficiency (GHD) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Growth Hormone Deficiency (GHD), historical and forecasted epidemiology as well as the Growth Hormone Deficiency (GHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Growth Hormone Deficiency (GHD) market report provides current treatment practices, emerging drugs, Growth Hormone Deficiency (GHD) market share of the individual therapies, current and forecasted Growth Hormone Deficiency (GHD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Growth Hormone Deficiency (GHD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Growth Hormone Deficiency (GHD) is a condition where the pituitary gland is unable to make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic). GHD may be caused by a tumor in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause GHD, which is known as acquired GHD (AGHD). However, in rare cases, GHD can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of GHD is not known or idiopathic.

Growth Hormone Deficiency (GHD) Market
                          Growth Hormone Deficiency (GHD) Market

View Free Sample Page:- https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Growth Hormone Deficiency Treatment

The DelveInsight Growth Hormone Deficiency (GHD) market report gives a thorough understanding of the Growth Hormone Deficiency (GHD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.  This segment of the report covers the detailed diagnostic methods or tests for Growth Hormone Deficiency (GHD).  It covers the details of conventional and current medical therapies available in the Growth Hormone Deficiency (GHD) market for the treatment of the condition. It also provides Growth Hormone Deficiency (GHD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Growth Hormone Deficiency Pipeline

The dynamics of the GHD market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Key players, such as Ascendis Pharma, Pfizer, Opko health, Lumos Pharma, and others are actively involved in developing new drugs for GHD. Ascendis Pharma is developing TransCon Hgh, which is an investigational long-acting prodrug in phase III clinical development stage as a once-weekly therapy for children with GHD. The company stated that TransConhGH has the potential to be the best-in-class long-acting hGH therapy. In 2020, the company held two pre-BLA meetings with the US FDA to review the chemistry, manufacturing and controls (CMC), and clinical/non-clinical packages for TransCon hGH as a potential treatment for pediatric GHD. The company also claims that it is on track to file a Biologics License Application with the FDA in the second quarter of 2020 and a Marketing Authorization Application to the EMA in the fourth quarter of 2020. The drug has received Orphan Designation in GHD from the FDA in April2020. Additionally, in October 2019, the drug had also received Orphan Designation in pediatric GHD from the European Commission.

Growth Hormone Deficiency Report Scope

  • The report covers the descriptive overview of Growth Hormone Deficiency (GHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Growth Hormone Deficiency (GHD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Growth Hormone Deficiency (GHD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Growth Hormone Deficiency (GHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Growth Hormone Deficiency (GHD) market.

Download Free Sample Page:- https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Table of content

1. Key Insights

2. Executive Summary of Growth Hormone Deficiency (GHD)

3. Competitive Intelligence Analysis for Growth Hormone Deficiency (GHD)

4. Growth Hormone Deficiency (GHD): Market Overview at a Glance

5. Growth Hormone Deficiency (GHD): Disease Background and Overview

6. Patient Journey

7. Growth Hormone Deficiency (GHD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Growth Hormone Deficiency (GHD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Growth Hormone Deficiency (GHD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Growth Hormone Deficiency (GHD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Growth Hormone Deficiency (GHD) market
  • To understand the future market competition in the Growth Hormone Deficiency (GHD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Growth Hormone Deficiency (GHD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Growth Hormone Deficiency (GHD) market
  • To understand the future market competition in the Growth Hormone Deficiency (GHD) market.

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

End-Stage Renal Disease (ESRD) Market Statistics, Facts & Figures, Growth Overview, Size & Share

(Albany,US) DelveInsight has launched a new report on End-Stage Renal Disease Market 

DelveInsight’s “End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD) , historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The End-Stage Renal Disease (ESRD) market report provides current treatment practices, emerging drugs, End-Stage Renal Disease (ESRD) market share of the individual therapies, current and forecasted End-Stage Renal Disease (ESRD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current End-Stage Renal Disease (ESRD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

End-stage renal disease (ESRD) also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10–15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks. Patients may experience a wide variety of symptoms as kidney failure progresses. These include fatigue, drowsiness, decrease in urination or inability to urinate, dry skin, itchy skin, headache, weight loss, nausea, bone pain, skin and nail changes, and easy bruising. Some of the risk factors for developing chronic kidney disease—that could ultimately lead to end-stage renal failure—include diabetes, high blood pressure, heart disease, drug abuse, blockages in the urinary tract, family history, inflammation, and some genetic disorders.

End-Stage Renal Disease (ESRD) Market
                                     End-Stage Renal Disease (ESRD) Market

View Free Sample Page:-  https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market

End-stage renal disease Treatment

The DelveInsight End-Stage Renal Disease (ESRD) market report gives a thorough understanding of the End-Stage Renal Disease (ESRD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.  This segment of the report covers the detailed diagnostic methods or tests for End-Stage Renal Disease (ESRD) It covers the details of conventional and current medical therapies available in the End-Stage Renal Disease (ESRD) market for the treatment of the condition. It also provides End-Stage Renal Disease (ESRD) treatment algorithms and guidelines in the United States, Europe, and Japan.

End-stage renal disease Market Outlook

Kidney failure, also called end-stage renal disease (ESRD), is the last stage of chronic kidney disease. There is no cure for ESRD, but many people live long lives while on dialysis (hemodialysis or peritoneal dialysis) or after having a kidney transplant. According to the National Kidney Foundation, more than 17,000 kidney transplants were performed in the United States in 2014.

People with diabetes or hypertension should control their conditions to help prevent ESRD. Both conditions benefit from drug therapy using angiotensin-converting enzyme inhibitors (ACE inhibitors/ACEi) or angiotensin receptor blockers (ARBs). ACEi/ARB therapy not only reduces proteinuria (and albuminuria) but decreases the yearly number of diabetic patients going on to require dialysis. Reduced hyper-filtration is consistent with the clinical observation and the introduction of ACEi/ARB therapy is associated with an acute decrease in estimated glomerular filtration rate (eGFR) and the fact that greater eGFR reductions were associated with less long-term loss of renal function. Although ACEi/ARB therapy slows renal functional loss in DN, it by no means induces remission or even halts progression to ESRD.

End-stage renal disease Report Scope

  • The report covers the descriptive overview of End-Stage Renal Disease (ESRD) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the End-Stage Renal Disease (ESRD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for End-Stage Renal Disease (ESRD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of End-Stage Renal Disease (ESRD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global End-Stage Renal Disease (ESRD) market

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market

Table of content

1. Key Insights

2. Executive Summary of End-Stage Renal Disease (ESRD)

3. Competitive Intelligence Analysis for End-Stage Renal Disease (ESRD)

4. End-Stage Renal Disease (ESRD) : Market Overview at a Glance

5. End-Stage Renal Disease (ESRD) : Disease Background and Overview

6. Patient Journey

7. End-Stage Renal Disease (ESRD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of End-Stage Renal Disease (ESRD) Treatment

11. Marketed Products

12. Emerging Therapies

13. End-Stage Renal Disease (ESRD) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of End-Stage Renal Disease (ESRD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the End-Stage Renal Disease (ESRD) market
  • To understand the future market competition in the End-Stage Renal Disease (ESRD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease (ESRD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease (ESRD) market
  • To understand the future market competition in the End-Stage Renal Disease (ESRD) market

Related Report

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Nonalcoholic Steatohepatitis (NASH) Market Statistics, Facts & Figures, Growth Overview, Size & Share

(Albany,US) DelveInsight has launched a new report on Nonalcoholic Steatohepatitis Market 

DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, Nonalcoholic Steatohepatitis (NASH) market share of the individual therapies, current and forecasted Nonalcoholic Steatohepatitis (NASH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.

Non-Alcoholic Steatohepatitis (NASH) Market
Non-Alcoholic Steatohepatitis (NASH) Market

View Free sample page:- https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis Treatment

The DelveInsight Nonalcoholic Steatohepatitis (NASH) market report gives a thorough understanding of the Nonalcoholic Steatohepatitis (NASH) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.  This segment of the report covers the detailed diagnostic methods or tests for Nonalcoholic Steatohepatitis (NASH).  It covers the details of conventional and current medical therapies available in the Nonalcoholic Steatohepatitis (NASH) market for the treatment of the condition. It also provides Nonalcoholic Steatohepatitis (NASH) treatment algorithms and guidelines in the United States, Europe, and Japan.

Nonalcoholic Steatohepatitis Pipeline

Due to the unmet need for an approved therapy for the treatment of NASH, several companies have shifted their focus toward the development of targeted drugs with a novel mechanism of action. Key players in the market of NASH are Genfit, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Conatus Pharmaceuticals, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Akcea Therapeutics, Second Genome Therapeutics, Oramed Pharmaceuticals, Ascletis and others. We expect that the launch of emerging therapies will fill the void treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies, and the market is expected to reach billions.

Nonalcoholic Steatohepatitis Report Scope

  • The report covers the descriptive overview of Nonalcoholic Steatohepatitis (NASH), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Nonalcoholic Steatohepatitis (NASH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Nonalcoholic Steatohepatitis (NASH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Nonalcoholic Steatohepatitis (NASH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.

Download Free Sample Page:- https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Table of content

1. Key Insights

2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)

3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis (NASH)

4. Nonalcoholic Steatohepatitis (NASH): Market Overview at a Glance

5. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview

6. Patient Journey

7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment

11. Marketed Products

12. Emerging Therapies

13. Nonalcoholic Steatohepatitis (NASH): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis (NASH)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Nonalcoholic Steatohepatitis (NASH) market
  • To understand the future market competition in the Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) market
  • To understand the future market competition in the Nonalcoholic Steatohepatitis (NASH) market

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

 

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Acute lymphocytic leukemia (ALL) Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Acute Lymphocytic Leukemia Pipeline

Acute lymphocytic leukemia (ALL) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute lymphocytic leukemia (ALL) market. A detailed picture of the Acute lymphocytic leukemia (ALL) pipeline landscape is provided, which includes the disease overview and Acute lymphocytic leukemia (ALL) treatment guidelines. The assessment part of the report embraces in-depth Acute lymphocytic leukemia (ALL) commercial assessment and clinical assessment of the Acute lymphocytic leukemia (ALL) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute lymphocytic leukemia (ALL) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts. ALL are caused by a lack of normal circulating blood cells. The exact causes of ALL remain largely unknown, but it is thought to result from mutations in one or more of the genes that normally control blood cell development. This mutation will result in abnormal growth. It is mainly classified into B-cell and T-cell ALL. ALL can occur at any age but is more common in young children (0–14 years) and it develops quickly, so people are usually only unwell for only a short period of time before they are diagnosed. Among children, B-cell lineage ALL constitutes approximately 88% of cases. Among adults, B-cell lineage represents around 75% of cases.

View Free Sample Page:- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight

Acute lymphocytic leukemia Pipeline

The dynamics of the ALL market is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Key players, such as Pharmacyclics, Incyte Corporation, Bristol-Myers Squibb, Roche, Novartis Pharmaceuticals, Janssen Research & Development, Servier, BioLine Rx, Sanofi, Jazz Pharmaceuticals, Gilead Sciences and others are involved in developing drugs for ALL.

Jazz Pharmaceuticals is investigating JZP-458 for the treatment for pediatric and adult patients with ALL who are hypersensitive to E. coli-derived asparaginases. JZP-458 is a recombinant of Erwinia asparaginase which uses a novel Pseudomonas fluorescens manifestation platform. A Phase I study in healthy volunteers in the US met safety and efficacy objectives with efficacy based on the measurement of serum asparaginase activity levels. Based on which, the company planned to initiate a single-arm, pivotal Phase II/III study evaluating JZP-458 as a potential treatment option for patients with ALL or LBL who are hypersensitive to E.coli-derived asparaginase products.

In October 2019, the US Food and Drug Administration (FDA) granted Fast Track Designation for JZP-458/PF743 for the treatment of ALL Jazz plans to file for approval of JZP-458 for ALL as early as the fourth quarter of 2020. Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing proapoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization, and the activation of caspases. It is currently being investigated in a Phase III trial for the treatment of patients with ALL.

Gamida Cell is investigating their lead clinical product, NiCord (Omidubicel), which is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). According to the company, Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the US FDA and has also received Orphan Drug Designation in the US and EU. This product is under investigation for the treatment of hematological malignancies in Phase III clinical trial.

Sanofi is investigating isatuximab (SAR650984) in Phase II clinical trial for the treatment of pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia in first or second relapse. It is a humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The company anticipates the regulatory submission of isatuximab for pediatric ALL in 2023.

Marketed drugs included in the report

  • Asparlas (calaspargase pegol-mknl): Servier Pharmaceuticals
  • Blincyto (blinatumomab/MT 103): Amgen
  • Kymriah (tisagenlecleucel): Novartis Pharmaceuticals
  • Besponsa (inotuzumabozogamicin): Pfizer
  • Erwinaze (asparaginase Erwinia chrysanthemi): Jazz Pharmaceuticals/Porton Biopharma Limited
  • Iclusig (ponatinib): Takeda (Ariad Pharmaceuticals)
  • and many others

Emerging therapies included in the report

  • Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)
  • Jakafi (ruxolitinib): Incyte Corporation/Novartis
  • Motixafortide (BL-8040): BioLine Rx
  • TC-110: TCR2 Therapeutics
  • Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb
  • TBI-1501: Takara Bio/Otsuka Pharmaceuticals
  • and many others

Acute lymphocytic leukemia Pipeline Report Scope

  • The Acute lymphocytic leukemia (ALL) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acute lymphocytic leukemia (ALL) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Acute lymphocytic leukemia (ALL) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Acute lymphocytic leukemia (ALL) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acute lymphocytic leukemia (ALL).

Download Free Sample Page:- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight

Table of content

1. Report Introduction

2. Acute lymphocytic leukemia (ALL)

3. Acute lymphocytic leukemia (ALL) Current Treatment Patterns

4. Acute lymphocytic leukemia (ALL) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acute lymphocytic leukemia (ALL) Late Stage Products (Phase-III)

7. Acute lymphocytic leukemia (ALL) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute lymphocytic leukemia (ALL) Discontinued Products

13. Acute lymphocytic leukemia (ALL) Product Profiles

14. Acute lymphocytic leukemia (ALL) Key Companies

15. Acute lymphocytic leukemia (ALL) Key Products

16. Dormant and Discontinued Products

17. Acute lymphocytic leukemia (ALL) Unmet Needs

18. Acute lymphocytic leukemia (ALL) Future Perspectives

19. Acute lymphocytic leukemia (ALL) Analyst Review

20. Appendix

21. Report Methodology

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

 

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Psoriatic Arthritis Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Psoriatic Arthritis Pipeline

Psoriatic Arthritis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Psoriatic Arthritis market. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided, which includes the disease overview and Psoriatic Arthritis treatment guidelines. The assessment part of the report embraces in-depth Psoriatic Arthritis commercial assessment and clinical assessment of the Psoriatic Arthritis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory arthritis that affects joints and tendons. Some of the people with psoriasis (featured with red patches of skin topped with silvery scales) are diagnosed with psoriatic arthritis that may result in permanent joint damage and disability. They can affect any part of body, including fingertips and spine, Joint pain, stiffness, and swelling are the main signs and symptoms and can range from relatively mild to severe forms. In both psoriasis and psoriatic arthritis, disease flares may alternate with periods of remission. Of those with psoriatic arthritis, 40% have a family member with psoriasis or arthritis, suggesting heredity may play a role. Psoriatic arthritis can also result from an infection that activates the immune system. While psoriasis itself is not infectious, it might be triggered by a streptococcal throat infection, commonly known as strep throat.

Psoriatic Arthritis Pipeline
                                                              Psoriatic Arthritis Pipeline

View Free Sample Page:-  https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight

Psoriatic Arthritis Pipeline

Companies all over the globe are persistently working towards the development of new treatment therapies and the key players at the global level are Sun Pharma, UCB Biopharma, AbbVie, Gilead, among others.

Tildrakizumab (trade name Ilumya (USA)/Ilumetri (European Union)) is a monoclonal antibody approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the US and the EU. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease. It is being jointly developed by Sun Pharma and Merck for the treatment of PsA and currently in Phase III. The Phase II results of tildrakizumab in adults with active PsA found significant improvements in several signs and symptoms.

Bimekizumab is currently being developed by UCB Biopharma and is in Phase III development. Bimekizumab binds and neutralizes dual targets IL-17A and IL-17F, and prevent their interactions with the IL-17 receptors. IL-17A and IL-17F have similar pro-inflammatory functions and independently cooperate with other inflammatory mediators to drive chronic inflammation and damage across multiple tissues. The bimekizumab dual neutralization inhibits the release of proinflammatory cytokines, chemokines, and mediators of tissue damage and reduces IL-17-mediated contributions to autoimmune and inflammation. It is a potential novel therapeutic approach in psoriatic arthritis and associated with significantly improved outcomes in Phase II studies with acceptable safety profiles.

Risankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A) that binds with a high affinity to the p19 subunit of IL-23 cytokine 2, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues. It is developed in collaboration between Boehringer Ingelheim and AbbVie. Risankizumab was approved by the FDA for the treatment of moderate-to-severe plaque psoriasis. Risankizumab was approved in Japan for the treatment of psoriasis Vulgaris, psoriatic arthritis, generalized pustular psoriasis. It is currently in the Phase III stage for the treatment of PsA in the US and EU.

Marketed drugs included in the report

  • Adalimumab: AbbVie
  • Etanercept: Pfizer
  • Golimumab: Janssen Biotech

Emerging therapies included in the report

  • Tildrakizumab: Sun Pharma
  • Bimekizumab: UCB Biopharma
  • Risankizumab: AbbVie
  • Filbotinib: Gilead and Galapagos NV
  • Upadacitinib: AbbVie

Psoriatic Arthritis Pipeline Report Scope

  • The Psoriatic Arthritis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Psoriatic Arthritis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Psoriatic Arthritis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Psoriatic Arthritis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Psoriatic Arthritis

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight

Table of content

1. Report Introduction

2. Psoriatic Arthritis

3. Psoriatic Arthritis Current Treatment Patterns

4. Psoriatic Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Psoriatic Arthritis Late Stage Products (Phase-III)

7. Psoriatic Arthritis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriatic Arthritis Discontinued Products

13. Psoriatic Arthritis Product Profiles

14. Psoriatic Arthritis Key Companies

15. Psoriatic Arthritis Key Products

16. Dormant and Discontinued Products

17. Psoriatic Arthritis Unmet Needs

18. Psoriatic Arthritis Future Perspectives

19. Psoriatic Arthritis Analyst Review

20. Appendix

21. Report Methodology

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Allergic Conjunctivitis Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Allergic Conjunctivitis Pipeline

Allergic Conjunctivitis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Allergic Conjunctivitis market. A detailed picture of the Allergic Conjunctivitis pipeline landscape is provided, which includes the disease overview and Allergic Conjunctivitis treatment guidelines. The assessment part of the report embraces in-depth Allergic Conjunctivitis commercial assessment and clinical assessment of the Allergic Conjunctivitis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Allergic Conjunctivitis (AC) is an inflammation of the conjunctiva (a thin membrane covering the white part of the eye) due to allergy. It is often interchangeably known as Ocular Allergy; a common immunological hypersensitivity disorder.  AC is a bilateral and self-limiting inflammatory process, fundamentally caused by an IgE-mediated immune mechanism or immediate hypersensitivity mechanism resulting from direct contact of the allergen with the conjunctival surface in sensitized patients – triggering mast cell activation and the release of different mediators. According to the classification of ocular allergy proposed in 2006 by the International Ocular inflammation Society based on immunopathological mechanisms, allergic conjunctivitis (AC) is subdivided into seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), giant papillary conjunctivitis (GPC) and contact dermatoconjunctivitis (CDC) – with different manifestations, different clinical courses, different immunopathological characteristics, and variable responses to treatment.

Allergic Conjunctivitis Pipeline
                                                      Allergic Conjunctivitis Pipeline

View Free Sample Page:-  https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight

Allergic Conjunctivitis Pipeline

Companies all over the globe are persistently working towards the development of new treatment therapies, and some of the key players at the global level are Aldeyra Therapeutics, Ocular Therapeutics and others. Reproxalap (Aldeyra Therapeutics) is a small molecule covalent inhibitor of reactive aldehyde species (RASP), which are known to be higher in ocular and systemic inflammatory diseases. RASP cause the activation of intracellular inflammatory factors, including NF-kB, inflammasomes and Scavenger Receptor A. Reproxalap has demonstrated statistically significant and clinically relevant activity in late-phase clinical conditions. A 0.25% dose of the immune-modulating drug led to a statistically significant decrease in ocular itching and redness in a Phase II allergen chamber clinical methods study, compared to the vehicle. Currently, the drug is in phase III clinical study. Aldeyra expects to complete the clinical trial of topical ocular Reproxalap in the second half of 2020. Dextenza (Ocular Therapeutix) is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.

Marketed drugs included in the report

  • Zerivate: Nicox Ophthalmics Inc.
  • Elestat: Allergan

Emerging therapies included in the report

  • Reproxalap: Aldeyra Therapeutics
  • Dextenza: Ocular Therapeutix

Allergic Conjunctivitis Report Scope

  • The Allergic Conjunctivitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Allergic Conjunctivitis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Allergic Conjunctivitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Allergic Conjunctivitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Allergic Conjunctivitis.

Download Free Sample Page:- https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight

Table of content

1. Report Introduction

2. Allergic Conjunctivitis

3. Allergic Conjunctivitis Current Treatment Patterns

4. Allergic Conjunctivitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Allergic Conjunctivitis Late Stage Products (Phase-III)

7. Allergic Conjunctivitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Allergic Conjunctivitis Discontinued Products

13. Allergic Conjunctivitis Product Profiles

14. Allergic Conjunctivitis Key Companies

15. Allergic Conjunctivitis Key Products

16. Dormant and Discontinued Products

17. Allergic Conjunctivitis Unmet Needs

18. Allergic Conjunctivitis Future Perspectives

19. Allergic Conjunctivitis Analyst Review

20. Appendix

21. Report Methodology

Related Report

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Obstructive Sleep Apnea Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Obstructive Sleep Apnea Pipeline

Obstructive Sleep Apnea Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Obstructive Sleep Apnea (OSA) market. A detailed picture of the Obstructive Sleep Apnea (OSA) pipeline landscape is provided, which includes the disease overview and Obstructive Sleep Apnea (OSA) treatment guidelines. The assessment part of the report embraces in-depth Obstructive Sleep Apnea (OSA) commercial assessment and clinical assessment of the Obstructive Sleep Apnea (OSA) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea (OSA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Obstructive Sleep Apnea Syndrome (OSA) is a clinical disorder marked by frequent pauses in breathing during sleep accompanied by loud noises. It is a type of Sleep Disorder Breathing (SBD), which is characterized as repeated episodes of apnea and hypopnea which occurs as a result of obstruction of the airway by anatomical structures in mouth and back of the throat. It is defined as a number of apneas and hypopneas experienced per hour and is measured using Apnea-hypopnea Index or AHI. A positive diagnosis of OSA is made when AHI>5. There are two major types of SDB- Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA). Among these, OSA is the most common type which constitutes more than 85% of all the cases of SBD. It causes severe symptoms, such as excessive daytime somnolence, and is associated with significant cardiovascular morbidity and mortality.

Obstructive Sleep Apnea Pipeline
                                                      Obstructive Sleep Apnea Pipeline

View Free Sample Page:- https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight

Obstructive Sleep Apnea (OSA) Pipeline

The dynamics of Obstructive Sleep Apnoea market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecasted period of 2020–2030. There are presently two pipeline therapies under development for the treatment of Obstructive sleep apnea (OSA) namely Solriamfetol (Jazz Pharmaceuticals), Dronabinol (RespireRx) and Apnimed (AD036). While the former candidate drug is mainly targeted for providing symptomatic relief to the patients the later poses itself as a significant alternative to CPAP with the potential to work as a first-line therapy option.

Marketed drugs included in the report

  • Provigil: Teva Pharmaceuticals
  • Nuvigil: Teva Pharmaceuticals
  • Solriamfetol: Jazz Pharmaceuticals

Emerging therapies included in the report

  • AD036: Apnimed
  • Dronabinol: RespireRx Pharmaceuticals

Obstructive Sleep Apnea Report Scope

  • The Obstructive Sleep Apnea (OSA) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Obstructive Sleep Apnea (OSA) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Obstructive Sleep Apnea (OSA) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Obstructive Sleep Apnea (OSA) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Obstructive Sleep Apnea (OSA).

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight

Table of content

1. Report Introduction

2. Obstructive Sleep Apnea (OSA)

3. Obstructive Sleep Apnea (OSA) Current Treatment Patterns

4. Obstructive Sleep Apnea (OSA) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Obstructive Sleep Apnea (OSA) Late Stage Products (Phase-III)

7. Obstructive Sleep Apnea (OSA) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Obstructive Sleep Apnea (OSA) Discontinued Products

13. Obstructive Sleep Apnea (OSA) Product Profiles

14. Obstructive Sleep Apnea (OSA) Key Companies

15. Obstructive Sleep Apnea (OSA) Key Products

16. Dormant and Discontinued Products

17. Obstructive Sleep Apnea (OSA) Unmet Needs

18. Obstructive Sleep Apnea (OSA) Future Perspectives

19. Obstructive Sleep Apnea (OSA) Analyst Review

20. Appendix

21. Report Methodology

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Musculoskeletal Pain Pipeline & Clinical Trials 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Musculoskeletal Pain Pipeline

Musculoskeletal Pain Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Musculoskeletal Pain market. A detailed picture of the Musculoskeletal Pain pipeline landscape is provided, which includes the disease overview and Musculoskeletal Pain treatment guidelines. The assessment part of the report embraces in-depth Musculoskeletal Pain commercial assessment and clinical assessment of the Musculoskeletal Pain pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Musculoskeletal Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Musculoskeletal Pain affects the bones, muscles, ligaments, tendons, and nerves, with the pain ranging from mild to severe enough to interfere with day-to-day life. It may start suddenly and be short-lived, which is called acute pain. Pain that lasts for more time is called chronic pain. Musculoskeletal pain can be localized in one area, or widespread. The most common cause of musculoskeletal pain is an injury to the bones, joints, muscles, tendons, or ligaments. Falls, sports injuries, and car accidents are just a few of the incidents that can lead to pain. People with musculoskeletal pain sometimes complain that their entire bodies ache. Their muscles may feel like they have been pulled or overworked. Sometimes, the muscles twitch or burn. Symptoms vary from person to person, but the common symptoms are Pain, Fatigue, Sleep disturbances. The most effective way to manage pain is with multidisciplinary pain management and the use of self-management. In a small number of cases, the condition may be improved with joint replacement surgery or the implantation of a spinal cord stimulator by a specially trained pain specialist. Chronic musculoskeletal pain conditions are multifaceted, and approximately 20% of the adult population lives with severe chronic pain, with a higher prevalence in women and lower-income groups.

View Free Sample Page:-  https://www.delveinsight.com/sample-request/musculoskeletal-pain-pipeline-insight

Musculoskeletal Pain Pipeline 

DelveInsight has performed detailed historical market analysis for Musculoskeletal Pain. In the coming years, the competitive landscape for the Musculoskeletal Pain market is set to change due to rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The launch of emerging therapies such, Tanezumab (Eli Lilly/Pfizer), Fasinumab (Regeneron Pharmaceuticals), MPC-06-ID (Mesoblast), CAM2038 (Braeburn Pharmaceuticals), and others will significantly impact the Musculoskeletal Pain market during the study period (2017-2030). While some of the companies have recently shifted their focus towards this indication, yet others are expected to create a significant influence on the market size during the forecast period. Tanezumab (Eli Lilly/Pfizer) is an investigational monoclonal antibody that works by selectively targeting, binding to, and inhibiting NGF. NGF levels increase in the body as a result of injury, inflammation, or chronic pain states. By inhibiting NGF, it may help to keep pain signals produced by muscles, skin, and organs from reaching the spinal cord and brain.

Recently US FDA accepts regulatory submission For Tanezumab, a potential first-in-class treatment for patients with chronic pain due to moderate-to-severe osteoarthritis. The US FDA has also granted Fast Track designation for Tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Fasinumab (Regeneron Pharmaceuticals) is an investigational therapy invented by Regeneron using the company’s proprietary VelocImmune technology that yields optimized fully-human antibodies. Fasinumab targets nerve growth factor (NGF), a protein that plays a central role in the regulation of pain signaling. There is evidence that NGF levels are elevated in the synovial fluid of patients with chronic pain conditions. Regeneron Pharmaceuticals is conducting the phase III trial of the product for the treatment of Osteoarthritis pain of the knee or hip in collaboration with Teva and Mitsubishi Tanabe. CAM2038 (Braeburn Pharmaceuticals) is an investigational buprenorphine weekly and monthly depot subcutaneous injection for the treatment of moderate-to-severe opioid use disorder and moderate-to-severe chronic pain. The company is conducting the phase II trial for chronic pain. Braeburn is also investigating CAM2038 in opioid-tolerant patients with chronic pain.  In a nutshell, the dynamics are changing to a large extent and the coming years will be something to look out for in the treatment landscape of Musculoskeletal Pain due to the launch of upcoming therapies.

Emerging therapies included in the report

  • Tanezumab: Eli Lilly/Pfizer
  • Fasinumab: Regeneron Pharmaceuticals
  • CAM2038: Braeburn Pharmaceuticals

Musculoskeletal Pain Pipeline Report Scope

  • The Musculoskeletal Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Musculoskeletal Pain across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Musculoskeletal Pain therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Musculoskeletal Pain research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Musculoskeletal Pain.

Download Free Sample Page:- https://www.delveinsight.com/sample-request/musculoskeletal-pain-pipeline-insight

Table of content

1. Report Introduction

2. Musculoskeletal Pain

3. Musculoskeletal Pain Current Treatment Patterns

4. Musculoskeletal Pain – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Musculoskeletal Pain Late Stage Products (Phase-III)

7. Musculoskeletal Pain Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Musculoskeletal Pain Discontinued Products

13. Musculoskeletal Pain Product Profiles

14. Musculoskeletal Pain Key Companies

15. Musculoskeletal Pain Key Products

16. Dormant and Discontinued Products

17. Musculoskeletal Pain Unmet Needs

18. Musculoskeletal Pain Future Perspectives

19. Musculoskeletal Pain Analyst Review

20. Appendix

21. Report Methodology

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Psoriatic Arthritis Epidemiology Forecast to 2030 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Psoriatic Arthritis Epidemiology

DelveInsight’s ‘Psoriatic Arthritis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory arthritis that affects joints and tendons. Some of the people with psoriasis (featured with red patches of skin topped with silvery scales) are diagnosed with psoriatic arthritis that may result in permanent joint damage and disability. They can affect any part of body, including fingertips and spine, Joint pain, stiffness, and swelling are the main signs and symptoms and can range from relatively mild to severe forms. In both psoriasis and psoriatic arthritis, disease flares may alternate with periods of remission.

View Free Sample Page:-  https://www.delveinsight.com/sample-request/psoriatic-arthritis-epidemiology-forecast

Psoriatic Arthritis Epidemiology

There are five types of PsA. Symmetric PsA affects the same joints on both sides of the body, both the left and right knees. Symmetric PsA tends to be milder and causes less joint deformity than RA. However, symmetric PsA can be disabling. Asymmetric PsA affects a joint or joints on one side of the body. It is generally mild. Distal interphalangeal predominant PsA involves the joints closest to the nails called as distal joints. Spondylitis PsA causes stiffness in the back or neck, and difficulty in bending. Psoriatic arthritis also can cause tender spots where tendons and ligaments join onto bones. This condition, called enthesitis, can result in pain at the back of the heel, the sole, around the elbows, or in other areas. Enthesitis is one of the characteristic features of psoriatic arthritis. Psoriatic arthritis mutilans is a severe, deforming type of PsA. It usually affects hands and feet. It can also cause pain in neck and lower back. To diagnose psoriatic arthritis, rheumatologists look for swollen and painful joints, certain patterns of arthritis, and skin and nail changes typical of psoriasis. X-rays often are taken to look for joint damage. MRI, ultrasound, or CT scans can be used to look at the joints in more detail. Blood tests may be done to rule out other types of arthritis that have similar signs and symptoms, including gout, osteoarthritis, and rheumatoid arthritis. In patients with psoriatic arthritis, blood tests may reveal high levels of inflammation and mild anemia but labs may also be normal. Occasionally skin biopsies (small samples of skin removed for analysis) are needed to confirm the psoriasis.

No cure for psoriatic arthritis exists, so the focus is on controlling symptoms and preventing damage to joints. For most people, appropriate treatments will relieve pain, protect the joints, and maintain mobility. Physical activity helps maintain joint movement. Without treatment, psoriatic arthritis may be disabling.

Psoriatic Arthritis Key Facts

  • Psoriatic arthritis affects about 20-30% of people with psoriasis. At times, arthritis can appear before the skin disorder. Psoriatic arthritis usually appears in people between the ages of 30 to 50, but sometimes may begin in childhood. Children with psoriatic arthritis are also at risk to develop uveitis (inflammation of the middle layer of the eye). Men and women are equally at risk. PsA affects every population equally, with a prevalence of approximately 1 to 2 per 1000 in the general population.
  • As per Gladman et al. (n.d.), the prevalence of psoriasis among patients with arthritis in the general population is 2–3%, but among patients with arthritis, it is 7%. Inflammatory arthritis occurs in 2–3% of the general population, but among patients with psoriasis, the prevalence of inflammatory arthritis varies from 6% to 42%. Thus, there is a distinct increase in the prevalence of inflammatory arthritis with varied presentation. The genetic epidemiology of PsA also supports its unique status. PsA has been associated with human leukocyte antigen (HLA) class 1 alleles as opposed to the class 2 alleles associated with RA.
  • According to the National Psoriasis Foundation, psoriatic arthritis affects about 1 million people in the United States or about 30% of all persons with psoriasis. The global average prevalence of psoriatic arthritis is 133 per 100,000 population (107–164 per 100,000). The exact prevalence of PsA is unknown and its estimation has been difficult, partly due to the lack of a widely accepted classification or diagnostic criteria, and partly since even experts may fail to make the correct diagnosis.

Psoriatic Arthritis Report Scope

  • The Psoriatic Arthritis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Psoriatic Arthritis Epidemiology Report and Model provide an overview of the risk factors and global trends of Psoriatic Arthritis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Psoriatic Arthritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Psoriatic Arthritis
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/psoriatic-arthritis-epidemiology-forecast

Table of content

1. Key Insights

2. Executive Summary of Psoriatic Arthritis

3. Psoriatic Arthritis: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this report?

  • The Psoriatic Arthritis Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Psoriatic Arthritis market
  • Quantify patient populations in the global Psoriatic Arthritis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Psoriatic Arthritis therapeutics in each of the markets covered
  • Understand the magnitude of Psoriatic Arthritis population by its epidemiology
  • The Psoriatic Arthritis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Shruti Thakur

[email protected]

+91-9650213330